|Bid||52.01 x 800|
|Ask||52.30 x 800|
|Day's range||51.66 - 53.25|
|52-week range||36.15 - 85.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||74.01|
CureVac majority shareholder says goal is for 100 million doses by end of 2020.
The Tesla car plant is slated for completion mid-2021.
CureVac is a leading German biotech in the race to develop a COVID-19 vaccine